Literature DB >> 7448363

The uptake of enzymes into lysosomes: an overview.

E F Neufeld.   

Abstract

Although it is possible to introduce enzymes and other proteins into lysosomes by nonspecific or "fluid" endocytosis, this process is very inefficient. Efficiency and selectivity are provided by the interaction of receptors on the cell surface and specific markers on the protein. Because most lysosomal enzymes are glycoproteins, the carbohydrate recognition systems are particularly relevant to their uptake. The systems that have been discovered are cell-specific and recognize the following terminal sugar residues: mammalian hepatocytes, galactose (also N-acetylgalactosamine, glucose) and L-fucose; avian hepatocytes, N-acetylglucosamine; mammalian reticuloendothelial cells, mannose (also N-acetylglucosamine, glucose); human fibroblasts, mannose 6-phosphate. Because of the ubiquity of mannose-terminated oligosaccharide chains on lysosomal enzymes derived from tissues, the reticuloendothelial system is probably of major importance in clearing injected enzymes from the circulation. The mannose 6-phosphate recognition system probably functions in directing endogenous enzymes, synthesized by fibroblasts, to the lysosomes of these cells. The existence of cell-specific recognition systems presents a challenge to future attempts at enzyme replacement in lysosomal storage diseases; enzymes will have to be selected or modified to have the appropriate marker for uptake by the cells where storage occurs.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7448363

Source DB:  PubMed          Journal:  Birth Defects Orig Artic Ser        ISSN: 0547-6844


  24 in total

Review 1.  New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders.

Authors:  Silvia Muro
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010 Mar-Apr

Review 2.  Targeted endothelial nanomedicine for common acute pathological conditions.

Authors:  Vladimir V Shuvaev; Jacob S Brenner; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

3.  Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders.

Authors:  Silvia Muro
Journal:  Drug Deliv Transl Res       Date:  2012-06-01       Impact factor: 4.617

Review 4.  The early and late processing of lysosomal enzymes: proteolysis and compartmentation.

Authors:  A Hasilik
Journal:  Experientia       Date:  1992-02-15

5.  Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.

Authors:  Janet Hsu; Daniel Serrano; Tridib Bhowmick; Kishan Kumar; Yang Shen; Yuan Chia Kuo; Carmen Garnacho; Silvia Muro
Journal:  J Control Release       Date:  2010-11-01       Impact factor: 9.776

6.  Altered Clathrin-Independent Endocytosis in Type A Niemann-Pick Disease Cells and Rescue by ICAM-1-Targeted Enzyme Delivery.

Authors:  Jeff Rappaport; Rachel L Manthe; Carmen Garnacho; Silvia Muro
Journal:  Mol Pharm       Date:  2015-04-23       Impact factor: 4.939

Review 7.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

Review 8.  Review: the immunochemical analysis of enzyme from mucopolysaccharidoses patients.

Authors:  D A Brooks
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

9.  Bone marrow transplant in a case of mucopolysaccharidosis I Scheie phenotype: skin ultrastructure before and after transplantation.

Authors:  C Navarro; C Dominguez; M Costa; J J Ortega
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

10.  Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases.

Authors:  David G Nathan; Stuart H Orkin
Journal:  Genome Med       Date:  2009-12-09       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.